AMD Flashcards

1
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

RF for AMD

A

AGE! Female HTN, hyperchol, CVD, FHx Smoking Hyperopia Light iris color White

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are 2 major susceptibility genes for AMD

A

CFH (1q31) - codes for complement factor H ARMS2 (10q26) - gene product poorly understood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Where are basal laminar and basal linear deposits?

A

Basal laminar - between the plasma membrane and the basement membrane of the RPE

Basal linear - within the inner collagenous zone of Bruch membrane (memo basal linear is in Bruchs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the size categories for drusen?

What is a drusenoid PED?

A

Small (< 67 um)

Intermediate (63-124 um)

large (>125 um) – 125 um width of blood vessel

drusenoid PED: confluent large drusen that coalesce into a PED (>350 um)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

AREDS study: Risk of progression to stage 4 AMD in patients with stage 2 and stage 3? what is defined by stage 2/3?

A

Over a 5 year period risk of progression to stage 4

Stage 2: many small drusen or few intermediate drusen. 1.3%

Stage 3: many intermediate drusen or even a single large druse (stage 3). 18%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

4 types of drusen

how do soft and hard drusen show up on FA?

Findings on OCT?

A

hard: discrete and well demarcated. well-defined focal areas of lipidization or hyalinization of the RPE-bruch membrane complex.

  • Typically window defect on FA
  • OCT: sub RPE elevations or small RPE detachments with no IRF and SRF

soft: amorphous and poorly demarcated. diffuse thickening of hte inner aspects of the bruch membrane (basal linear deposits) - more likely to progress to atrophy or CNV than an eye with only hard drusen.

  • Typically slowly and homogenously stain late because of pooling of FA in the sub-PED compartment.
  • OCT: sub RPE elevations or small RPE detachments with no IRF and SRF

Reticular pseudodrusen: seen on FAF, smaller then soft drusen, superior macular region, associated with progressive atrophy, GA, CNV.

  • OCT - above the RPE

Drusen in pts < 50: familial or early-onste drusen. Include: large colloid drusen, malattia leventinese, and cuticular drusen.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the patterns of abnormalities of the RPE in AMD

A
  1. Focal hyperpigmentation. Typically blockage on FA and hyperreflective outer retinal foci on SD-OCT.
  2. nongeographic atrophy. atrophy that does not cover a contiguous area and may appear as mottling or depigmentation
  3. geographic atrophy: area of absent RPE is contiguous. Choroidal vessels more visible, outer retina thin, choriocapillaris attenuated. Window defects on FA, OCT loss of RPE and inner segments ellipsoid and photoreceptor layer. Dense hypoautoF on FAF. Often fovea involvement LATE in disease process.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Ddx for nonneovascular AMD

A

CSC

Pattern dystrophy

adult-onset vitelliform maculopathy

drug toxicity (ie plaquenil)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

AREDS 2 results at 5 and 10 years. Definition of intermediate and advanced AMD?

A

Intermediate or advanced AMD

  • At 5 years
    • 25% risk reduction for progression
    • 19% risk reduction in rates of moderate vision loss
  • At 10 years
    • 44% of placebo vs 34% of supplement eyes had advanced AMD (27% RR)

Definition of intermediate and advanced:

  • Intermediate (stage 3): at least 1 large druse, 10 or more intermediate drusen or nonsubfoveal GA
  • Advanced (stage 4): nAMD, GA in only one eye
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is are the 4-points on the 4-point grading scale developed by AREDS for classifying the severity of AMD?

A
  • presence of 1 or more large (>125-µm diameter) drusen (1 point)
  • presence of any pigment abnormalities (1 point)
  • for patients with no large drusen, presence of bilateral intermediate (63–124 µm) drusen (1 point)
  • presence of neovascular AMD (2 points)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the AREDS2 vitamins with doses?

A

Vitamin C 500 mg

Vitamin E 400 IU

Lutein 10 mg

Zeaxanthin 2 mg

Zinc 80 mg

(VVLZZ)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Findings in AREDS2 study?

A

Lutein and zeaxanthin similar effect to beta carotene

LCPUFA not helpful

Lung cancer in pts who previously smoked taking beta carotene

conclusion: replace beta carotene with lutein and zeaxanthin and NOT add LCPUFAs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Clinical signs of CNV in AMD?

A

SRF

IRF

exudate and/or blood

pigment ring or gray-green membrane

irregular elecation of the RPE or a PED

RPE tear

sea fan pattern of subretinal vessels

intraretinal blood and CME may indicate type 3 NV (from the deep capillary plexus of the retinal circulation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are the 3 types of CNV in nAMD?

A

type 1: sub-RPE

  • vascularized serous or fibrovascular PED

type 2: sub-retinal

  • lacy or gray-green lesion

type 3

  • new vessels sprouting from the deep capillary plexus (RAP retinal angiomatous proliferation)
  • –> if these lesions progress they lead to a hypertrophic, fibrotic, disciform scar*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

FA patterns of CNV?

A

Classic: bright, lacy, well-defined ((can be typically related to type 2))

Occult: ((can be typically related to type 1))

  1. PED
  2. Late leakage from undefined source
17
Q

OCT patterns of CNV

  • Type 1 serous PED
  • Type 1 fibrovascular PED
  • Chronic fibrovascular PED
  • Type 2
  • Type 3
A
  • Type 1 serous PED: sharply elevated, dome-shaped lesions with hollow internal reflectivity and no assocaited SRF or IRF
  • Type 1 fibrovascular PED: lacy or polyplike hyperreflective lesion on the undersurfance of the RPE
  • Chronic fibrovascular PED: multilayed appearance
  • Type 2 neovascular membranes: hyperreflective band or plaque in the subneurosensory space (with SRF or IRF)
  • Type 3 neovascular membranes: hyperreflective focus emanating from the deep capillary plexus of the retina (with out without CME and PED)
18
Q

Polypoidal choroidal vasculopathy

A

variant of type 1

serosanguineous RPE detachments

network of polyps (string of pearls)

typically hypertensive middle aged women (initially found in asian or african american ancestry)

often peripapillary and multifocal

OCT and ICG useful for identifying the lesions

20
Q

MARINA findings

A
  • Objective: Lucentis/Ranibizumab (2 doses 0.3mg or 0.5mg) or sham for occult CNV
  • Result
  • 95% of lucentis eyes had Va improvement or stabilization compared with 62% of control eyes
  • Close to 40% of lucentis eyes has Va improvement > 15 letters compared with control eyes

Conclusion

  • Ranibizumab better than sham for occult or minimally classic CNV from AMD
21
Q

ANCHOR

A

•Objective: Ranibizumab/lucentis vs PDT in classic CNV

Result

  • Prevent vision loss: 95% lucentis eyes vs 64% PDT eyes
  • Loss of <15 letters Va: 90% of lucentis eyes, 65% of PDT

Conclusion

  • Ranibizumab is superior to PDT for predominantly classic CNV from AMD
22
Q

VIEW1/2

A

Objective: Evaluate 3 dosing regimens for eylea: 0.5mg q4wks, 2mg q4wks, 2mg q8wks following initial monthly injections vs lucentis 0.5mg q4wks

Conclusion

Eylea q8wks equivalent to lucentis monthly after 3 monthly loading doses

23
Q

CATT

A

•Objective

Objective: Avastin vs lucentis with monthly and PRN dosing

Conclusion

  • VA outcomes not statistically significant monthly vs PRN dosing
  • Mean gain greater for monthly vs PRN
  • Avastin noninferior to lucentis
  • systemic adverse events greater in the avastin group
  • Arterial thrombotic event similar between drugs